Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial
Authors
- John Raymond Zalcberg (ORCID: https://orcid.org/0000-0002-6624-0782)
- Craig R. Underhill (ORCID: https://orcid.org/0000-0001-9335-2678)
- Desmond Yip (ORCID: https://orcid.org/0000-0002-2806-2401)
- Val Gebski (ORCID: https://orcid.org/0000-0001-8748-1844)
- Hans A. J. Gelderblom (ORCID: https://orcid.org/0000-0001-9270-8636)
- Mikael Eriksson (ORCID: https://orcid.org/0000-0001-8135-4270)
- Jean‐Yves Blay (ORCID: https://orcid.org/0000-0001-7190-120X)
- Neeltje Steeghs (ORCID: https://orcid.org/0000-0003-2989-2279)
- Kjetil Boye (ORCID: https://orcid.org/0000-0002-5552-6283)
- Antoîne Italiano (ORCID: https://orcid.org/0000-0002-8540-5351)
- Sandrine Marréaud (ORCID: https://orcid.org/0000-0002-3205-3858)
- Timothy Jay Price (ORCID: https://orcid.org/0000-0002-3922-2693)
- Heikki Joensuu (ORCID: https://orcid.org/0000-0003-0281-2507)
- David Espinoza
- John Simes
Institutions
- Australian National University (AU)
- Oslo University Hospital (NO)
- The University of Sydney (AU)
- Lund University (SE)
- Leiden University Medical Center (NL)
- Helsinki University Hospital (FI)
- Canberra Hospital (AU)
- The Netherlands Cancer Institute (NL)
- Queen Elizabeth Hospital (AU)
- Centre Léon Bérard (FR)
- Albury Wodonga Health (AU)
- European Organisation for Research and Treatment of Cancer (BE)
- Institut Bergonié (FR)
- Skåne University Hospital (SE)
- National Health and Medical Research Council (AU)
- Monash University (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1038/s41416-025-02983-w
- Citations
- 2
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.62